Brisdelle is licensed to treat hot flashes caused by menopause. It comes in the form of a capsule that is taken once daily at bedtime. The medication is a type of selective serotonin reuptake inhibitor and is the first non-hormonal drug approved by the FDA for treating hot flashes associated with menopause. Side effects can include headaches, nausea, and fatigue.
What Is Brisdelle?
Brisdelle™ (paroxetine mesylate capsules) is a prescription medication approved to treat hot flashes associated with menopause. It belongs to a class of medicines known as selective serotonin reuptake inhibitors (SSRIs). Brisdelle is the first non-hormonal medication approved by the U.S. Food and Drug Administration (FDA) for treating hot flashes due to menopause.
As mentioned, Brisdelle belongs to a class of medicines called selective serotonin reuptake inhibitors (SSRIs). SSRIs work to increase serotonin activity by increasing the amount of serotonin available in the small space between the cells in the body.
Serotonin has many functions in the body, including effects on mood and behavior. It is unknown how Brisdelle works to reduce hot flashes, but it is likely related to the drug's effects on serotonin. It is thought that changes in serotonin levels somehow contribute to the development of hot flashes during menopause.
The ability of SSRIs to reduce hot flashes is independent of their effects on mood. This is the reason Brisdelle works to treat hot flashes in doses that are lower than those that would be needed to treat depression or anxiety.
Food and Drug Administration. FDA approves the first non-hormonal treatment for hot flashes associated with menopause (July 2, 2013). FDA Web site. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm359030.htm. Accessed August 23, 2013.
Imai A, Matsunami K, Takagi H, Ichigo S. New generational nonhormonal management for hot flashes. Gynecol Endocrinol 2013;29(1):63-66.
Shams T, Firwana B, Habib F, Alshahrani A, AlNouh B, Murad MH, Ferwana M. SSRIs for hot flashes: a systemic review and meta-analysis of randomized trials. J Gen Intern Med 2013 Jul 26. [Epub ahead of print].
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed August 23, 2013.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed August 23, 2013.
National Library of Medicine (US). Hazardous Substances Data Bank (HSDB). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB. Accessed August 23, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click